Most Read Articles
Naomi Rodrig, 27 Apr 2016

LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]

Naomi Rodrig, 28 Apr 2016
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Pearl Toh, 13 May 2017
Short-term use of oral corticosteroids was associated with increased risks of adverse events such as fracture, sepsis, and venous thromboembolism (VTE), a large US cohort study showed.
Naomi Rodrig, 03 May 2016
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.

What are the risk factors for impaired balance control in COPD?

01 Dec 2016

Balance impairment in patients with chronic obstructive pulmonary disease (COPD) may be directly related to old age, coronary artery disease, increased Timed Up and Go (TUG), and reduced 6-minute walk distance (6MWD), according to a study presented at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) in Bangkok, Thailand.

The study included 102 patients with stable COPD aged ≥60 years. Balance was evaluated using the Berg Balance Scale (BBS), wherein a score of ≤46 indicated a deficit in balance control.

Of the patients, 27.5 percent had impaired balance. Demographic data, disease-related characteristics, TUG and 6MWD were compared between patients with impaired and nonimpaired balance.

A multivariable logistic regression model showed that the odds of having impaired balance were greater among COPD patients who were older (age ≥80 years; odds ratio [OR], 6.90; 95 percent CI, 1.23 to 38.54; by 2.74; p=0.028), with coronary artery disease (OR, 6.39; 1.06 to 38.65; p=0.043), had 6MWD <300 m (OR, 13.57; 1.87 to 98.24; p=0.010) and had TUG ≥13.5 sec (OR, 9.15; 1.76 to 47.54; p=0.008).

Female gender had a nonsignificant association with balance impairment (OR, 3.43; 0.59 to 19.82; p=0.169).

“The model explained 71.1 percent of the variance in balance impairment,” researchers said.

COPD is a common preventable and treatable disease, characterized by persistent airflow limitation. This disease occurs comorbidly with many non-respiratory conditions such as skeletal muscle dysfunction, systemic inflammation, nutritional depletion, malnutrition, as well as balance control deficit.

Evidence suggests that the ability to maintain stability and balance is essential for functional independence in activities of daily living, mobility and for avoiding falls. An increased risk of falls can lead to a higher mortality rate among older adults. [PLoS One 2015;10:e0120573]

Given the findings, balance testing should be included in routine assessment of COPD in order to prevent falls and reduce its devastating consequences, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 27 Apr 2016

LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]

Naomi Rodrig, 28 Apr 2016
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Pearl Toh, 13 May 2017
Short-term use of oral corticosteroids was associated with increased risks of adverse events such as fracture, sepsis, and venous thromboembolism (VTE), a large US cohort study showed.
Naomi Rodrig, 03 May 2016
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.